Clinical Trial

Tornier HRS (Humeral Reconstruction System) Study (REVIVE)

Study acronym: REVIVE
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is an international, single arm, multicenter, prospective follow-up, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available Tornier HRS (HUMERAL RECONSTRUCTION SYSTEM) shoulder system in both the anatomic and reversed configurations. Retrospective inclusions are allowed: study patients may be enrolled up to 3 months after date of surgery provided that the necessary pre-operative (baseline) and surgery data are accessible. Follow-up visits conducted from 3-month post-surgery onward must be prospective. The purpose of this study is to collect data needed to satisfy the European Union (EU) Medical Device Regulation (MDR) clinical post-market surveillance (PMS) and reporting requirements, and to support future regulatory submissions and peer-reviewed publications on device performance and safety.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-08-11; most recent amendment 2026-03-24.
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-01-11
Trial Details
NCT Number NCT05500066
Lead Sponsor Stryker Trauma and Extremities
Conditions Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis, Correction of Functional Deformity, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains, Rotator Cuff Tears
Enrollment 110 participants
Start Date 2023-01-11
Primary Completion 2028-01-06 (estimated)
Study Completion 2036-01-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-30